Vision

For more than two decades, Elan has created science and developed disease-modifying treatments that are defining the future of degenerative neurological therapies.

We see the brain as the last great frontier in scientific research and therapy development. There is no greater challenge and no greater opportunity to make a meaningful difference in patients' lives.

Elan has a long history as a pioneer in treating neurodegenerative diseases. We have generated the core science and fundamental discoveries responsible for breakthrough compounds that profoundly impact disease ranging from multiple sclerosis to Alzheimer’s disease and Parkinson’s disease. These discoveries have been fostered by a culture of scientific innovation and risk-taking; and unfettered freedom to innovate, to pursue new therapies.

We are focused on translating our science from the laboratories, and on using our unique drug technologies, to develop and deliver new therapies to patients. Our marketed therapies – including Tysabri for the treatment of multiple sclerosis and Crohn’s disease– provide important treatments for patients with unmet medical needs.

Our employees are committed to moving our pipeline from laboratory to clinic to the market place. We collaborate with many of the world’s leading biotech and pharmaceutical companies to maximize the potential of our science and accelerate bringing new therapies to market.

We are working every day to become the leading neuroscience company in the world, as we discover new science and deliver new therapies to help millions of patients around the world.

More than a vision, we see this as a moral responsibility.

What it Means: